RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.
- Mechanism
- Curator reviewed
RIGScan CR49 is used to locate cancerous tissue during surgery for patients with metastatic cancer of the colon or rectum (colorectal). In multicenter Phase II and pivotal Phase III clinical trials, RIGScan CR49 located tumor confirmed by pathology tests in 90 percent of evaluable patients who participated in the studies. The product found pathology-confirmed tumor that was missed by the surgeon and by preoperative diagnostic scans in one of five of the evaluable patients.
- Primary indication
- Investigated for use/treatment in colorectal cancer and solid tumors.Curator reviewed
- Also known as
- RIGScan CR · RIGScan CR49
- Code names
- NAV-1800
What you can answer from here — as of March 06, 2025
Which companies are running trials of NAV 1800, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account